XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.3

Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Percentage of Product Sales and Accounts Receivable Balance

The following table includes the percentage of product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our product sales:

		Product Sales								Accounts Receivable
		Three Months Ended September 30, 2023				Nine Months Ended September 30, 2023				As of September 30, 2023
Customer A			43.6	%			42.7	%			44.7	%
Customer B			37.3	%			37.2	%			37.0	%
Customer C			18.5	%			19.1	%			18.0	%
Total			99.4	%			99.0	%			99.7	%

Schedule of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):

		Three Months Ended September 30,								Nine Months Ended September 30,
		2023				2022				2023				2022
CINVANTI net product sales		$	23,270			$	21,169			$	70,599			$	64,173
SUSTOL net product sales			3,439				2,671				9,258				7,179
ZYNRELEF net product sales			4,372				2,717				12,033				6,292
APONVIE net product sales			353				—				921				—
Total net product sales		$	31,434			$	26,557			$	92,811			$	77,644

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):

		Product Returns				Distributor Fees				Discounts, Rebates and Administrative Fees				Total
Balance at December 31, 2022		$	3,336			$	4,180			$	25,801			$	33,317
Provision			2,092				17,420				128,232				147,744
Payments/credits			(921	)			(17,335	)			(127,194	)			(145,450	)
Balance at September 30, 2023		$	4,507			$	4,265			$	26,839			$	35,611

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):

		September 30,
		2023				2022
Stock options outstanding			31,317				20,500
Restricted stock units outstanding			1,786				2,817
Warrants outstanding			298				8,548
Shares of common stock underlying convertible notes outstanding			9,819				9,819

X

- Definition

Schedule of disaggregated net product sales.

+ References

No definition available.

+ Details

Name:	hrtx_ScheduleOfDisaggregatedNetProductSalesTableTextBlock
Namespace Prefix:	hrtx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.

+ References

No definition available.

+ Details

Name:	hrtx_ValuationAllowancesAndReservesTableTextBlock
Namespace Prefix:	hrtx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration